Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of preservative-free tafluprost + timolol fixed-dose combination vs individual monotherapies in open-angle glaucoma or ocular hypertension
2010-022965-82Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Nov 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ocular hypertension, open-angle glaucoma (OAG), pseudoexfoliation glaucoma (PXG) and 1 more comparing Preservative-free tafluprost + timolol FDC, Tafluprost monotherapy and Timolol monotherapy (3 arms). Started Nov 2010; status: completed.
02
Drugs
tafluprosttimolol
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)pseudoexfoliation glaucoma (PXG)pigmentary glaucoma (PG)
Beyond the preview
Go deeper on 2010-022965-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022965-82.